Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on November 26, 2025. The filing discloses the execution of new employment agreements with three key executives: David J. Moss (President and CEO), Cory Ellspermann (CFO), and Mark Lowdell (Chief Scientific Officer). The agreements are effective as of November 1, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
| Executive | Role | Base Salary | Target Bonus | Equity Grant |
|---|---|---|---|---|
| David J. Moss | President & CEO | $500,000 | 50% of base | 800,000 shares |
| Cory Ellspermann | CFO | $275,000 | 40% of base | 300,000 shares |
| Mark Lowdell | CSO | £300,000 | Up to 20% of base | Not specified in summary |
Material Changes
The primary material change is the formalization of compensation structures for the company's top leadership team. Notably, Mr. Lowdell's agreement is with the company's wholly-owned subsidiary, INmune Bio International Limited, with costs potentially recharged to the parent company.
Guidance, Risks, and Unusual Items
Severance Provisions: The agreements for Mr. Moss and Mr. Ellspermann include significant severance packages in the event of Involuntary Termination, consisting of 18 months of base salary, a prorated bonus, and COBRA premiums for up to 18 months. Mr. Lowdell is entitled to 18 months of base salary as severance if terminated without cause.
Change of Control: Equity options granted to Mr. Moss and Mr. Ellspermann will immediately vest upon a Change of Control, provided they remain employed until the closing date.
Outlook: The filing text does not provide financial guidance or management commentary on future business prospects.
Investor Verification Checklist
- Verify the total number of shares available under the 2021 Stock Incentive Plan to assess the dilution impact of the 1.1 million new options granted.
- Review the full text of Exhibits 10.1, 10.2, and 10.3 for specific definitions of "Involuntary Termination" and "Change of Control."
- Confirm the exchange rate impact and total cost of Mr. Lowdell's compensation given the GBP-denominated salary.
- Assess the potential cash outflow liability for severance packages (18 months of salary) in the event of executive turnover.